Zydus Lifesciences Limited has reported strong financial results for the third quarter and nine months ended December 31, 2025. The company’s revenue for Q3 FY26 stood at Rs. 68,645 million, showing a growth of 30% compared to the same period last year. Net profit (adjusted) for the quarter was Rs. 11,109 million, up 9% year-on-year. EBITDA increased by 31% to Rs. 18,164 million, with margins improving to 26.5%. For the nine-month period, revenue reached Rs. 1,95,614 million, marking a 17% growth, while adjusted net profit rose 15% to Rs. 38,640 million.
The India formulations business recorded revenue of Rs. 17,094 million in Q3, growing 13% year-on-year, driven by strong performance in chronic therapies such as cardiology, respiratory, dermatology, oncology, and nephrology. The North America formulations business reported revenue of Rs. 28,043 million, up 16%, supported by new product launches and approvals. During the quarter, the company launched four new products in the US and received approval for eight ANDAs. Zydus also received USFDA approval for Zycubo®, the first and only approved therapy for Menkes disease, a rare disorder.
The Consumer Wellness segment saw exceptional growth of 113% year-on-year, mainly due to the consolidation of Comfort Click Limited. The MedTech business also contributed positively, reporting Rs. 2,996 million in revenue during the quarter. On the regulatory front, the company’s manufacturing facilities received positive inspection reports from the USFDA.
Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, said the strong performance reflects the strength of the company’s core businesses and its focused strategy on innovation, compliance, and global expansion. The company remains committed to long-term growth and delivering value to patients and shareholders worldwide.
These results show that Zydus Lifesciences is growing steadily, improving profits, and managing its business efficiently, which can build confidence about future returns and long-term value. Strong revenue growth, better margins, and new product approvals, especially in the US market indicate stability and expansion potential.
